C12N 2770/32434
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32434 (Use of virus or viral component as vaccine) appears on 87 US grants and 47 published applications in this corpus.
Search patents in C12N- Granted patents
- 87
- Published applications
- 47
- Assignees
- 52
- Inventors
- 199
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 4 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 6 | 0 |
| 1997 | 2 | 0 |
| 1998 | 6 | 0 |
| 1999 | 2 | 0 |
| 2000 | 6 | 0 |
| 2001 | 4 | 0 |
| 2002 | 3 | 3 |
| 2003 | 2 | 6 |
| 2004 | 2 | 3 |
| 2005 | 4 | 2 |
| 2006 | 2 | 1 |
| 2007 | 1 | 1 |
| 2008 | 2 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 2 | 4 |
| 2015 | 1 | 2 |
| 2016 | 2 | 3 |
| 2017 | 3 | 1 |
| 2018 | 4 | 1 |
| 2019 | 1 | 1 |
| 2020 | 2 | 3 |
| 2021 | 1 | 2 |
| 2022 | 2 | 3 |
| 2023 | 2 | 3 |
| 2024 | 1 | 1 |
| 2025 | 1 | 2 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Hepatitis A virus preparation method and hepatitis A virus prepared according to method24 Feb 2026US 12,558,417 B2SK Bioscience Co., Ltd.
- Methods for preventing dengue and hepatitis a21 Jan 2025US 12,201,683 B2Takeda Vaccines, Inc.
- Identifying patient populations vulnerable to viral infection and methods of inducing heterologous immunity in same26 Mar 2024US 11,938,181 B2nference, Inc.
- Neisseria meningitidis compositions and methods thereof22 Aug 2023US 11,730,800 B2Pfizer Inc.
- Dengue vaccine unit dose and administration thereof28 Feb 2023US 11,590,221 B2Takeda Vaccines, Inc.
- Methods for preventing dengue and hepatitis a25 Sep 2025US 2025/0295761 A1Takeda Vaccines, Inc.
- Hepatitis a virus preparation method and hepatitis a virus prepared according to method29 May 2025US 2025/0170234 A1SK Bioscience Co., Ltd.
- Identifying patient populations vulnerable to viral infection and methods of inducing heterologous immunity in same6 Jun 2024US 2024/0181043 A1nference, Inc.
- Neisseria meningitidis compositions and methods thereof28 Dec 2023US 2023/0414737 A1Pfizer Inc.
- Dengue vaccine unit dose and administration thereof9 Nov 2023US 2023/0355748 A1Takeda Vaccines, Inc.
Most cited
By later US patents
- Adjuvant systems and vaccines92US 7,357,936 B1SmithKline Beecham Biologicals s.a. · 2008
- Recombianant Hepatitis a virus59US 5,294,548 AAmerican Biogenetic Sciences, Inc. · 1994
- Vaccine34US 6,013,264 ASmithKline Beecham Biologicals s.a. · 2000
- Combined vaccine compositions31US 6,932,972 B2SmithKline Beecham Biologicals s.a. · 2005
- Process for the preparation of a lyophilized vaccine against duck virus hepatitis30US 4,622,222 APhylaxia Oltoanyagtermelo Vallalat · 1986